Fig. 3: Rapamycin treatment reduces arthritis severity and bone erosion in IL1rn−/− mice.
From: mTORC1 links pathology in experimental models of Still’s disease and macrophage activation syndrome
a Representative depiction of ankle inflammation, (b) hematoxylin and eosin staining of ankle sections, (c) histologic scores of ankle arthritis (vehicle, n = 10; rapamycin n = 11), (d) ankle and wrist thickness (vehicle, n = 14; rapamycin n = 11), (e) composite arthritis score (vehicle, n = 14; rapamycin n = 11) and (f, g) micro-CT quantification of joint erosion in IL1rn−/− mice treated with rapamycin or vehicle for 10 weeks. h Ankle and wrist joint measurements (n = 8 per group) and (i) composite arthritis score (n = 5 per group) in IL1rn−/− mice with established arthritis treated with vehicle or rapamycin for 2 weeks. j Flow cytometry quantification of Ly6Chi monocytes and neutrophils in the bone marrow and k) synovial fluid of IL1rn−/− mice treated with vehicle control or rapamycin for 10 weeks (n = 5 per group). Data in (c–e, g–j, k) were pooled from 2 to 3 independent experiments. Mice were 4 weeks old for experiments in (a–g, j, k) and 10 weeks old for experiments in (h, i). Statistical analyses (all two-sided): Mann–Whitney U test (c, g, j, k); Student’s t test (d, e, h, i). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Median and error bars representing interquartile range are displayed in (c, g, j, k). Mean and error bars representing standard errors are displayed in (d, e, h, i). Source data are provided as a Source Data file.
